Navigation Links
Novartis Gains FDA Approval for Amturnide™, a Triple-Combination Pill to Treat High Blood Pressure in Patients Uncontrolled on Two Medications
Date:12/22/2010

EAST HANOVER, N.J., Dec. 22, 2010 /PRNewswire/ -- Today Novartis announced that the US Food and Drug Administration (FDA) approved Amturnide (aliskiren, amlodipine and hydrochlorothiazide) tablets for the treatment of high blood pressure. Amturnide combines the only approved direct renin inhibitor worldwide, Tekturna (aliskiren), with the widely used calcium channel blocker amlodipine and the diuretic hydrochlorothiazide (HCTZ).

The FDA approval was based on data from a double-blind, active controlled study, which showed that Amturnide provided significantly greater reductions in blood pressure compared to all dual combinations of its components. Amturnide is approved for patients whose blood pressure is not adequately controlled with any two of its individual components and is not indicated as initial therapy for high blood pressure. Amturnide is only the third high blood pressure treatment to combine three drugs in a single-pill.

"The FDA approval of Amturnide provides an important treatment option to help address the complex needs of high blood pressure patients," said Andre Wyss, President of Novartis Pharmaceuticals Corporation. "This approval emphasizes our commitment to cardiovascular research and to developing innovative and effective treatments for patients who have not reached their blood pressure goal."

The study involved 1,181 patients with moderately elevated blood pressure (mean systolic blood pressure [mSBP] 160-179 mmHg) or severely elevated blood pressure (mSBP >/=180 mmHg). Both patient populations achieved greater systolic and diastolic blood pressure reductions with Amturnide compared to dual combination treatment of aliskiren/amlodipine 300 mg/10 mg, aliskiren/HCTZ 300 mg/25 mg, and amlodipine/HCTZ 10 mg/25 mg.

In the overall patient population, Amturnide reduced systolic/diastolic blood pressure by an additional 9.9/6.3 mmHg compared to aliskiren/HCTZ; 7.2/3.6 mmHg compared to amlodipine/HCTZ; and 6.6/2.6 mmHg
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients
2. Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients
3. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
4. Final Approval of Novartis Gender Discrimination Settlement Slated for November 19
5. Study in NEJM Shows Novartis Drug Afinitor® Reduces Size of SEGAs, Benign Brain Tumors Associated with Tuberous Sclerosis
6. VIDEO from thenewsmarket.com and Novartis: Novartis drug Afinitor® Approved by FDA as First Medication for Children and Adults With a Benign Brain Tumor Associated With Tuberous Sclerosis
7. Novartis to Expand Global Research Headquarters in Cambridge, MA
8. VIDEO From thenewsmarket.com and Novartis: Phase III Data Show That Novartis Meningococcal Vaccine Menveo® Demonstrated Robust Immunogenicity in Infants
9. Analysis Shows Novartis Drug TOBI® Associated With Reduced Mortality in Cystic Fibrosis Patients With Common Lung Infection
10. Long-Term Data Show Novartis Once-Yearly Reclast Preserves Bone Mass and Provides Fracture Protection in Postmenopausal Osteoporosis
11. Novartis Committed to Supporting Patients and Healthcare Professionals with Education Programs and Support Services that Enhance Access to Gilenya
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Russia,s ... The Pharma 2020 Strategy provides incentives for local producers ... and foreign markets. These trends, however, were affected by ... following political and economic sanctions imposed on ... Russia responded to the ...
(Date:9/16/2014)... 2014 Research and Markets ... Laparoscopy Devices Industry Report 2014" report to ... Devices Industry Report 2014 is a professional and ... global laparoscopic devices. The report provides ... classifications, applications and industry chain structure. The laparoscopic ...
(Date:9/16/2014)... Sept. 16, 2014 Based on its ... Frost & Sullivan recognises Incisive Surgical with the ... Value Leadership. Incisive Surgical,s uniquely-designed, innovative INSORB® Absorbable ... eliminates the need for patients to undergo the ... removal  that may result in increased pain, wound ...
Breaking Medicine Technology:Global Medicines for Russia 2Global Laparoscopy Devices Industry Report 2014 2Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 2Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 3Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 4Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 5
(Date:9/16/2014)... (PRWEB) September 16, 2014 Transparency Market ... that the global facial care market is expected to ... The report, titled ‘Facial Care Market (By Product Type ... Wash, Cleansing Wipes, Serums and Masks and Others (fade ... Share, Growth, Trends and Forecast 2013 – 2019,’ is ...
(Date:9/16/2014)... 2014 Whatisfinalexpenseinsurance.com has released a ... affordable life insurance for seniors. , Finding affordable life ... A big part of the insurance market has moved ... tips that clients can use when shopping for life ... is important for providing financial security for vulnerable family ...
(Date:9/16/2014)... is effective in diagnosing concussion-related brain disease while a ... conducted at the Icahn School of Medicine at Mount ... Haven, and published September 16 in the journal ... that an experimental radiolabeled compound called [18 F]-T807, which ... that accumulates in the brain with repetitive blows to ...
(Date:9/16/2014)... Researchers at the Hebrew University of Jerusalem have ... at coaxing adult cells to become quality pluripotent ... and expanding area that aims to replace lost ... transplantation. Because stem cells derived from human embryos ... reprogramming adult cells back to an embryo-like state ...
(Date:9/16/2014)... Gary F. Locke, the former U.S. Ambassador to ... Group for exclusive representation of his global speaking activities. ... of Washington, Locke is widely recognized as one of ... and business growth. , “Gary Locke provides audiences with ... an organization’s global presence in and with China,” stated ...
Breaking Medicine News(10 mins):Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 2Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 3Health News:Life Insurance for Seniors - Clients Can Find Fast Life Insurance By Comparing Online Quotes! 2Health News:Neuroimaging technique identifies concussion-related brain disease in living brain 2Health News:Neuroimaging technique identifies concussion-related brain disease in living brain 3Health News:Scientists create therapy-grade stem cells using new cocktail to reprogram adult cells 2Health News:Gary Locke, Former Ambassador to China, Selects Worldwide Speakers Group for Exclusive Lecture Representation 2
... cells in the human brain is linked to learning and ... Florida. The research is the first to show such a ... upcoming print issue of the journal Brain , provide ... and reveal potential cellular targets for drug therapy. The ...
... HealthDay Reporter , WEDNESDAY, Aug. 25 (HealthDay News) -- ... 2008, nearly one in four American parents with health insurance ... to access the medical care their children needed. Parents ... likely than others to say their insurance coverage did not ...
... Despite the fact that an estimated 25 million ... general anesthesia, scientists have only been able to hypothesize ... They previously thought that the processes of "going under" ... the same way. Now, researchers at the University of ...
... Va.SNM supports the U.S. Senate in its introduction of ... and Radiation Therapy Act of 2010 (CARE Act), S. ... by Sen. Mike Enzi [R-WY], aims to ensure that ... are set at the state level. The bill,s co-sponsors ...
... Melissa Lee Phillips HealthDay Reporter , WEDNESDAY, Aug. ... to an inheritable eye disease that affects 5 percent of ... for transplants of the cornea. The genetic disorder, ... the cornea -- the thin, clear membrane that covers the ...
... Reporter , WEDNESDAY, Aug. 25 (HealthDay News) -- U.S. ... U.S. judge to halt any expansion of stem cell ... basically blindsided the scientific community, effectively takes embryonic stem ... when then-President George W. Bush ordered that federal monies ...
Cached Medicine News:Health News:Scientists find link in humans between nerve cell production, memory 2Health News:Scientists find link in humans between nerve cell production, memory 3Health News:Even Before Recession, 14 Million Kids 'Underinsured': Study 2Health News:Even Before Recession, 14 Million Kids 'Underinsured': Study 3Health News:Penn study sheds light on how the brain shifts between sleep/awake states under anesthesia 2Health News:SNM applauds US Senate's introduction of CARE Act 2Health News:Study Links Gene to Serious Eye Disease 2Health News:Obama to Appeal Stem Cell Ruling 2Health News:Obama to Appeal Stem Cell Ruling 3
...
Liquichek Elevated CRP Control is a liquid assayed serum control with elevated levels of C-Reactive Protein....
LiquichekCardiac Markers Plus Control LT is a premium, comprehensive cardiac assessment control with many analytes and long stability....
Liquichek Cardiac Markers Plus Control is a premium, comprehensive cardiac assessment control with many analytes and long stability....
Medicine Products: